文献速递白血病

DHODH:治疗T细胞急性淋巴细胞白血病的一个有前景的靶点

DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

复发或难治性T细胞急性淋巴细胞白血病(T-ALL)患者预后差且治疗选择少。研究利用依赖图谱项目数据将二氢乳清酸脱氢酶(DHODH)鉴定为T-ALL最重要的代谢依赖靶点之一,在体外及3种T-ALL小鼠模型中证实T淋巴母细胞对DHODH抑制后的核苷酸饥饿高度敏感,并发现部分T-ALL亚群在DHODH抑制剂治疗时更依赖氧化磷酸化。

要点

  • DHODH是T-ALL最重要的代谢依赖靶点之一。
  • DHODH抑制导致嘧啶耗竭、DNA/RNA合成抑制和细胞死亡。
  • T淋巴母细胞对DHODH抑制后的核苷酸饥饿高度敏感。

核心结论

  • DHODH抑制所致的核苷酸饥饿可能区分白血病细胞与正常T细胞及其他正常造血细胞,提供可利用的治疗机会。
  • 已有处于人体临床试验的临床级DHODH抑制剂,提示该工作有潜力快速推进至临床。

研究设计与样本

  • 利用依赖图谱项目数据鉴定T-ALL的代谢依赖靶点,并在体外及3种T-ALL小鼠模型中验证。
  • 通过一系列代谢检测分析核苷酸饥饿下白血病细胞的线粒体膜电位变化及对替代燃料来源的依赖。
  • 在年轻小鼠中检查DHODH抑制对正常T细胞发育的影响。

主要发现

  • DHODH被鉴定为T-ALL最重要的代谢依赖靶点之一。
  • DHODH小分子抑制迅速耗竭细胞内嘧啶池,迫使细胞依赖胞外补救途径。
  • 补救不足时,细胞内核苷酸饥饿导致DNA和RNA合成抑制、细胞周期停滞并最终死亡。
  • T淋巴母细胞对DHODH抑制后的核苷酸饥饿似乎特别且高度敏感,已在体外及3种T-ALL小鼠模型中证实。
  • 部分T-ALL亚群在接受DHODH抑制剂治疗时似乎更依赖氧化磷酸化;白血病细胞在核苷酸饥饿下线粒体膜电位发生改变,可能更依赖替代燃料来源。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) have a poor prognosis with few therapeutic options. With the goal of identifying novel therapeutic targets, we used data from the Dependency Map project to identify dihydroorotate dehydrogenase (DHODH) as one of the top metabolic dependencies in T-ALL. DHODH catalyzes the fourth step of de novo pyrimidine nucleotide synthesis. Small molecule inhibition of DHODH rapidly leads to the depletion of intracellular pyrimidine pools and forces cells to rely on extracellular salvage. In the absence of sufficient salvage, this intracellular nucleotide starvation results in the inhibition of DNA and RNA synthesis, cell cycle arrest, and, ultimately, death. T lymphoblasts appear to be specifically and exquisitely sensitive to nucleotide starvation after DHODH inhibition. We have confirmed this sensitivity in vitro and in vivo in 3 murine models of T-ALL. We identified that certain subsets of T-ALL seem to have an increased reliance on oxidative phosphorylation when treated with DHODH inhibitors. Through a series of metabolic assays, we show that leukemia cells, in the setting of nucleotide starvation, undergo changes in their mitochondrial membrane potential and may be more highly dependent on alternative fuel sources. The effect on normal T-cell development in young mice was also examined to show that DHODH inhibition does not permanently damage the developing thymus. These changes suggest a new metabolic vulnerability that may distinguish these cells from normal T cells and other normal hematopoietic cells and offer an exploitable therapeutic opportunity. The availability of clinical-grade DHODH inhibitors currently in human clinical trials suggests a potential for rapidly advancing this work into the clinic.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sexauer AN, Alexe G, Gustafsson K, et al. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2023. PMID: 37648673. doi:10.1182/bloodadvances.2023010337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。